| __timestamp | Alnylam Pharmaceuticals, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 94231000 |
| Thursday, January 1, 2015 | 276495000 | 146394000 |
| Friday, January 1, 2016 | 382392000 | 188272000 |
| Sunday, January 1, 2017 | 390635000 | 166707000 |
| Monday, January 1, 2018 | 505420000 | 401843000 |
| Tuesday, January 1, 2019 | 655114000 | 560909000 |
| Wednesday, January 1, 2020 | 654819000 | 722343000 |
| Friday, January 1, 2021 | 792156000 | 771182000 |
| Saturday, January 1, 2022 | 883015000 | 877090000 |
| Sunday, January 1, 2023 | 1004415000 | 877387000 |
| Monday, January 1, 2024 | 1126232000 |
Data in motion
In the competitive landscape of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Alnylam Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc. have been at the forefront of this race since 2014. Over the past decade, Alnylam has consistently increased its R&D investment, culminating in a 428% rise by 2023. Meanwhile, Sarepta has also shown a robust growth trajectory, with a 831% increase in R&D spending over the same period.
Alnylam's R&D expenses surged from 19% of its 2014 levels to 100% in 2023, reflecting its strategic focus on pioneering RNA interference therapeutics. Sarepta, known for its work in genetic medicine, mirrored this trend, with its R&D spending reaching 88% of its 2023 levels. This data underscores the relentless pursuit of innovation by these biotech giants, shaping the future of medicine.
Research and Development: Comparing Key Metrics for Gilead Sciences, Inc. and Alnylam Pharmaceuticals, Inc.
GSK plc vs Alnylam Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
argenx SE or Sarepta Therapeutics, Inc.: Who Invests More in Innovation?
Alnylam Pharmaceuticals, Inc. vs Sarepta Therapeutics, Inc.: Annual Revenue Growth Compared
Alnylam Pharmaceuticals, Inc. vs Madrigal Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Galapagos NV
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs MiMedx Group, Inc.
BeiGene, Ltd. vs Sarepta Therapeutics, Inc.: Strategic Focus on R&D Spending
R&D Insights: How Sarepta Therapeutics, Inc. and Exelixis, Inc. Allocate Funds
R&D Insights: How Sarepta Therapeutics, Inc. and PTC Therapeutics, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and MannKind Corporation